| bibliographicCitation |
Dartigeas C, Quinquenel A, Ysebaert L, Dilhuydy M, Anglaret B, Slama B, Le Du K, Tardy S, Tchernonog E, Orfeuvre H, Voillat L, Guidez S, Malfuson J, Dupuis S, Deslandes M, Feugier P, Leblond V, Adiko D, Agape P, Auger Quittet S, Bareau B, Benbrahim O, Bernard P, Bescond C, Bijou F, Boudin L, Cailleres S, Calmettes C, Cartron G, Costello R, David S, Delaunay J, Delette C, Dennetiere S, Drenou B, El Yamani A, Delmer A, Fitoussi O, Fleck E, Fleury J, Gutnecht J, Hacini M, Jourdan É, Kaphan R, Karsenti J, Labourey J, Launay V, Le Calloch R, Leduc I, Lefrere F, Le Gall S, Le Goff M, Legouffe É, Le Gouill S, Lepretre S, Liu J, Luttiau Motard C, Moldovan M, Molina L, Moullet I, Peyrade F, Quittet P, Re D, Roland V, Roos-Weil D, Saad A, Saad H, Senecal D, Thannberger A, Thieblemont C, Tournilhac O, Visanica S, . Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study. Ann Hematol. 2024 Mar 06;(). doi: 10.1007/s00277-024-05666-3. |